VILNIUS — Five high-technology companies are set to invest 150 million litai (€43.47 million) to create a business park in Vilnius later this year.
Lithuania has been marketing itself as a good place to invest in for high end research facilities and as an ideal near shoring location. The country however has seen few investments over the last year into these fields. The new investment will help boost manufacturing exports, a sector that [private_supervisor]makes up a large chunk of the economy.
The Visorių IT Park will host companies from the medical, biopharmaceutical, solar energy technology research and experimental production facility fields.
More than one third of the investment will come from the EU from structural funds to invest into the 10,000 square meter IT park, whose construction will start this autumn.
The Ministry of Economy and the Lithuanian Business Support Agency signed grant agreements Monday with the companies Intersurgical, Sicor Biotech, ViaSolis, Baltic Solar Solutions and Baltic Solar Energy. Around 61.4 million litai (€17.7 million) will be funded by the EU.
“Focused promotion into the investment in high technology will become profitable for the Lithuanian economy after only 10 years. I want to emphasize that the added value of biotechnology in the developed solar cell manufacturing sector is five to seven times higher than in traditional industries,” Minister of Economy Dainius Kreivys said.
Visorių IT Park development director Saulius Arelis said the park would help develop exports and the academic community.
“Most of the new projects in Visorių are emerging technologies and the products will be exported, and therefore they will participate in shaping our country’s academic community. The planned investment will stimulate much business involvement in Lithuania and will also be an example for integrated science, education and business centers,” he said.
Head of Baltic Solar Energy, Vidmantas Janulevičius, said all the products would boost exports for the country. He said that within a decade, the solar cell cluster could have a turnover of 1.6 billion litai and should employ over 500 people.
The companies
Intersurgical has secured 14.9 million litai in funding and will use it to producte medical disposable respiratory products.
Sicor Biotech will receive 7.8 million litai from the EU support for the development of biopharmaceutical manufacturing.
ViaSolis secured 14.3 million litai from the EU to fund a production line for photovoltaic modules, to innovate production and for installation.
Baltic Solar Solutions and Baltic Solar Energy have secured 14.9 million litai and 9.5 million litai respectively. They will both work on experimental silicon cell power generation and develop a research center. [/private_supervisor] [private_subscription 1 month]makes up a large chunk of the economy.
The Visorių IT Park will host companies from the medical, biopharmaceutical, solar energy technology research and experimental production facility fields.
More than one third of the investment will come from the EU from structural funds to invest into the 10,000 square meter IT park, whose construction will start this autumn.
The Ministry of Economy and the Lithuanian Business Support Agency signed grant agreements Monday with the companies Intersurgical, Sicor Biotech, ViaSolis, Baltic Solar Solutions and Baltic Solar Energy. Around 61.4 million litai (€17.7 million) will be funded by the EU.
“Focused promotion into the investment in high technology will become profitable for the Lithuanian economy after only 10 years. I want to emphasize that the added value of biotechnology in the developed solar cell manufacturing sector is five to seven times higher than in traditional industries,” Minister of Economy Dainius Kreivys said.
Visorių IT Park development director Saulius Arelis said the park would help develop exports and the academic community.
“Most of the new projects in Visorių are emerging technologies and the products will be exported, and therefore they will participate in shaping our country’s academic community. The planned investment will stimulate much business involvement in Lithuania and will also be an example for integrated science, education and business centers,” he said.
Head of Baltic Solar Energy, Vidmantas Janulevičius, said all the products would boost exports for the country. He said that within a decade, the solar cell cluster could have a turnover of 1.6 billion litai and should employ over 500 people.
The companies
Intersurgical has secured 14.9 million litai in funding and will use it to producte medical disposable respiratory products.
Sicor Biotech will receive 7.8 million litai from the EU support for the development of biopharmaceutical manufacturing.
ViaSolis secured 14.3 million litai from the EU to fund a production line for photovoltaic modules, to innovate production and for installation.
Baltic Solar Solutions and Baltic Solar Energy have secured 14.9 million litai and 9.5 million litai respectively. They will both work on experimental silicon cell power generation and develop a research center. [/private_subscription 1 month] [private_subscription 4 months]makes up a large chunk of the economy.
The Visorių IT Park will host companies from the medical, biopharmaceutical, solar energy technology research and experimental production facility fields.
More than one third of the investment will come from the EU from structural funds to invest into the 10,000 square meter IT park, whose construction will start this autumn.
The Ministry of Economy and the Lithuanian Business Support Agency signed grant agreements Monday with the companies Intersurgical, Sicor Biotech, ViaSolis, Baltic Solar Solutions and Baltic Solar Energy. Around 61.4 million litai (€17.7 million) will be funded by the EU.
“Focused promotion into the investment in high technology will become profitable for the Lithuanian economy after only 10 years. I want to emphasize that the added value of biotechnology in the developed solar cell manufacturing sector is five to seven times higher than in traditional industries,” Minister of Economy Dainius Kreivys said.
Visorių IT Park development director Saulius Arelis said the park would help develop exports and the academic community.
“Most of the new projects in Visorių are emerging technologies and the products will be exported, and therefore they will participate in shaping our country’s academic community. The planned investment will stimulate much business involvement in Lithuania and will also be an example for integrated science, education and business centers,” he said.
Head of Baltic Solar Energy, Vidmantas Janulevičius, said all the products would boost exports for the country. He said that within a decade, the solar cell cluster could have a turnover of 1.6 billion litai and should employ over 500 people.
The companies
Intersurgical has secured 14.9 million litai in funding and will use it to producte medical disposable respiratory products.
Sicor Biotech will receive 7.8 million litai from the EU support for the development of biopharmaceutical manufacturing.
ViaSolis secured 14.3 million litai from the EU to fund a production line for photovoltaic modules, to innovate production and for installation.
Baltic Solar Solutions and Baltic Solar Energy have secured 14.9 million litai and 9.5 million litai respectively. They will both work on experimental silicon cell power generation and develop a research center. [/private_subscription 4 months] [private_subscription 1 year]makes up a large chunk of the economy.
The Visorių IT Park will host companies from the medical, biopharmaceutical, solar energy technology research and experimental production facility fields.
More than one third of the investment will come from the EU from structural funds to invest into the 10,000 square meter IT park, whose construction will start this autumn.
The Ministry of Economy and the Lithuanian Business Support Agency signed grant agreements Monday with the companies Intersurgical, Sicor Biotech, ViaSolis, Baltic Solar Solutions and Baltic Solar Energy. Around 61.4 million litai (€17.7 million) will be funded by the EU.
“Focused promotion into the investment in high technology will become profitable for the Lithuanian economy after only 10 years. I want to emphasize that the added value of biotechnology in the developed solar cell manufacturing sector is five to seven times higher than in traditional industries,” Minister of Economy Dainius Kreivys said.
Visorių IT Park development director Saulius Arelis said the park would help develop exports and the academic community.
“Most of the new projects in Visorių are emerging technologies and the products will be exported, and therefore they will participate in shaping our country’s academic community. The planned investment will stimulate much business involvement in Lithuania and will also be an example for integrated science, education and business centers,” he said.
Head of Baltic Solar Energy, Vidmantas Janulevičius, said all the products would boost exports for the country. He said that within a decade, the solar cell cluster could have a turnover of 1.6 billion litai and should employ over 500 people.
The companies
Intersurgical has secured 14.9 million litai in funding and will use it to producte medical disposable respiratory products.
Sicor Biotech will receive 7.8 million litai from the EU support for the development of biopharmaceutical manufacturing.
ViaSolis secured 14.3 million litai from the EU to fund a production line for photovoltaic modules, to innovate production and for installation.
Baltic Solar Solutions and Baltic Solar Energy have secured 14.9 million litai and 9.5 million litai respectively. They will both work on experimental silicon cell power generation and develop a research center. [/private_subscription 1 year]
— This is a paid article. To subscribe or extend your subscription, click here.
